Scientists at the Broad Institute of MIT and Harvard tested about 4,518 drugs on 578 human cancer cell lines, and discovered that almost 50 had previously unrecognized anti-cancer properties.

Boston Biomedical Inc. entered into an alliance in oncology research with three world-leading oncology centers of excellence – Columbia University, Harvard University and The Wistar Institute.

Over the past 50 years, the FDA has relied upon – and often deferred to – industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.

About a quarter of the dollars spent on healthcare in the United States may be wasted, a new analysis suggests.

A new study conducted by the Pacific Research Institute (PRI) found that wider adoption of biosimilars in the United States would create significant savings to state Medicaid programs and consumers with commercial insurance.

A new blood test in development from GRAIL Inc. and studied by investigators at the Dana-Farber Cancer Institute has the ability to accurately screen for numerous types of cancer.

Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.

GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.

A new study found that taking 4,000 international units per day may double the amount of vitamin D in the blood, but it gives most people roughly the same chance of developing blood sugar problems as people who do not take the vitamin.

Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine.